GeneDx Holdings Corp.

NASDAQ:WGS

Medical - Healthcare Information Services

Healthcare
$51.96 +2.69%

+$1.52 today

Market cap
$1.56B
Beta
1.97
P/E (TTM)
-21.8
EPS (TTM)
-$2.65
52W Low $32.21High $170.87

Volume 1.71M

Average 1.28M

WGS Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

GeneDx Holdings Corp.NASDAQ: WGS

Net Margin · Q2 FY2026 · quarter ended Jun 2026

Net margin narrows to -15.5%

Net margin was -15.5% in Q2 FY2026, down 26.0 pp from a year earlier. On a trailing-twelve-month basis it was -23.4%, down 23.8 pp year over year. Over 3 fiscal years it widened by 229.0 pp.

Context

  • Net margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 6 analysts of 2.2% for the fiscal year ending Dec 2026, up from -4.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-15.5%+46.4 pp QoQ
Last fiscal yearDec 2025
-4.9%+12.2 pp YoY
LTMJun 2026
-23.4%-23.8 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-26.0 pp+8.3 pp+34.3 pp
1 year+12.2 pp+7.1 pp-5.1 pp
3 years+229.0 pp+13.8 pp-215.2 pp
5 years+18.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-4.9%
Year-over-year change
+12.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How WGS compares with its peers on the latest reported figures

  • WGS's LTM Jun 2026 net margin of -23.4% is the 5th highest of the 9 companies compared; the peer median is -27.1%.
  • Its year-over-year change of -23.8 pp is the 6th highest of 9, against a peer median of -5.7 pp.
  • Over three fiscal years its change of +229.0 pp compares with a peer median of +27.7 pp.
WGS Competitors Peer median
Net Margin for WGS and competitors
Company Period LTM level YoY 3-year change
BLLNBillionToOne, Inc.LTM Jun 20268.4% +23.1 pp—
CSTLCastle Biosciences, Inc.LTM Mar 2026-3.8% -2.3 pp+42.0 pp
NEONeoGenomics, Inc.LTM Jun 2026-6.8% +8.3 pp+13.4 pp
FLGTFulgent Genetics, Inc.LTM Mar 2026-23.0% -9.1 pp-41.9 pp
WGSGeneDx Holdings Corp.LTM Jun 2026-23.4% -23.8 pp+229.0 pp
MDXHMDxHealth S.A.FY2025-31.1% +11.2 pp+87.8 pp
MYGNMyriad Genetics, Inc.LTM Mar 2026-48.2% -36.0 pp-27.9 pp
PSNLPersonalis, Inc.LTM Mar 2026-148.1% -50.0 pp—
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026-2454.6% -940.1 pp+6371.3 pp
Peer median (excluding WGS) -27.1%-5.7 pp+27.7 pp

Competitors are the stored peer set for WGS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue212.2M234.69M202.57M305.45M427.54M
Cost of Revenue228.8M261.44M112.56M111.05M129.37M
Gross Profit(16.6M)(26.75M)90.01M194.4M298.17M
Gross Margin-7.8%-11.4%44.4%63.6%69.7%
Research & Development105.16M86.2M58.27M45.72M72.03M
Selling, General & Admin318.73M338.24M194.71M168.48M239.22M
Operating Expenses429.55M640.9M270.6M217.61M311.25M
Depreciation & Amortization21.81M59.31M33.73M21.95M25.22M
EBITDA(220.75M)(398.2M)(136.46M)(27.64M)6.63M
EBITDA Margin-104.0%-169.7%-67.4%-9.1%1.5%
Operating Income(446.15M)(667.65M)(180.6M)(23.21M)(11.8M)
Operating Margin-210.3%-284.5%-89.2%-7.6%-2.8%
Interest Income79K2.54M1.11M00
Interest Expense2.84M3.21M03.03M2.54M
Other Income / Expenses200.76M69.62M3.9M(29.42M)(9.34M)
Income Before Tax(245.39M)(598.03M)(176.69M)(52.63M)(21.14M)
Pre-Tax Margin-115.6%-254.8%-87.2%-17.2%-4.9%
Income Tax Expense0(49.05M)(926K)(343K)(116K)
Net Income(245.39M)(548.98M)(175.77M)(52.29M)(21.02M)
Net Margin-115.6%-233.9%-86.8%-17.1%-4.9%
EPS (Basic)(74.93)(53.63)(7.23)(1.94)(0.73)
EPS (Diluted)(74.93)(53.63)(7.23)(1.94)(0.73)
Weighted Avg Shares3.28M10.24M24.31M26.89M26.89M
Weighted Avg Shares (Diluted)3.28M10.24M24.31M26.89M26.89M

GeneDx Holdings Corp.

NASDAQ:WGS

Intrinsic Alpha fair value

Locked

Current Price

$51.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.